Clinical Trial Update: RenalGuard System for Prevention of Contrast Induced Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for the RenalGuard System in preventing contrast-induced nephropathy. The current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• RenalGuard System

Snippet

Sponsor: Hospital Sao Lucas da PUCRS | Conditions: Radiographic Contrast Agent Nephropathy | Phase 3 | Status: UNKNOWN